Bionano Genomics, Inc. BNGOW 深 滬
交易中 03-26 09:50:27 美东时间
0.0036
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.0036
- 總市值 100.37万
- 52周最高 0.604
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.0019
- 委 比 0.00%
- 總股本 2.79亿
- 歷史最高 11.82
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.0019
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Bionano Genomics Earnings Call: Margin Gains, Growth Test
Bionano Genomics (($BNGO)) has held its Q4 earnings call. Read on for the main ...
03-24 08:02
Bionano Genomics reports Q4 results
Bionano Genomics press release (BNGO): Q4 net loss of $8M. Revenue of $8M (-2.4% Y/Y) beats by $0.12M. Sold 7,554 nanochannel array flowcells in the fourth quarter of 2025, representing a decrease of ...
03-24 04:11
Earnings Scheduled For March 23, 2026
Companies Reporting Before The Bell • Avalo Therapeutics (NASDAQ:AVTX) is likel...
03-23 19:11
Bionano Announces Two-Fold Increase in OGM Studies Presented At Annual Clinical Genetics Meeting
Bionano Genomics participated in the 2026 American College of Medical Genetics and Genomics Annual Meeting (ACMG), held March 14–18 in Baltimore, Maryland. Twelve studies, representing a two-fold increase over the number
03-17 20:02
Bionano Announces Two-Fold Increase in OGM Studies Presented at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
Bionano Genomics participated in the 2026 ACMG Annual Meeting, presenting 12 studies demonstrating the application of optical genome mapping (OGM) in detecting structural variants across cancer genomics and genetic disorders. The increase in study count highlights growing interest in OGM's capabilities, particularly in identifying complex genomic variations missed by other methods. Key presentations included clinical applications in pediatric rar...
03-17 12:00
Bionano to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call Webcast on March 23, 2026
Bionano Genomics will host a conference call and live webcast on Monday, March 23, 2026, at 4:30 p.m. ET to discuss Q4 and full-year 2025 financial results and recent corporate progress. Participants can access the webcast via the link provided on Bionano’s Investors page. A replay will be available on the company’s investor relations website for at least 30 days. For inquiries, contact Erik Holmlin, CEO, or investor relations through the provide...
03-09 20:05
9 Presentations Kick Off Day 1 of the Bionano Symposium 2026 Covering Advances in Optical Genome Mapping for Hematologic Malignancies
Bionano Genomics announced highlights from Day 1 of their 2026 Symposium focused on Optical Genome Mapping (OGM) advancements in hematologic malignancies. Experts demonstrated OGM's superior resolution and ability to detect structural variants compared to traditional methods like karyotyping and FISH. The virtual event attracted over 1,000 attendees globally, showcasing OGM's integration with NGS and its role in transforming cytogenetics workflow...
02-24 13:00
Bionano Genomics Publishes Study On Application Of Optical Genome Mapping To Trace Genomic Alterations Introduced By Different Gene Editing Technologies
Bionano Genomics, Inc. (Nasdaq: BNGO) announced a peer-reviewed study published in Molecular Therapy - Methods & Clinical Development, describing the application of optical genome mapping (OGM) to detect genomic
02-04 21:07
Bionano Reports Preliminary Fourth Quarter and Full-Year 2025 Results
Bionano Genomics reported preliminary Q4 and FY2025 financial results. Total Q4 revenue is expected to be $7.8M-$8.0M, a 2%-4% YoY decrease. FY2025 revenue is projected at $28.4M-$28.6M, down 7%-8% YoY. They sold 30,171 nanochannel array flowcells and installed 32 new OGM systems in FY2025. Notably, they achieved reimbursement progress with two new CPT codes, expanded clinical research evidence, and upgraded their software platforms. As of Dec 31...
01-12 13:00
Bionano Recaps Advances in Optical Genome Mapping Showcased at AMP 2025
Bionano Genomics participated in the 2025 AMP Annual Meeting, showcasing Optical Genome Mapping (OGM) technology for enhanced structural variant (SV) detection._presentations highlighted OGM's utility across inherited diseases, reproductive disorders, hematological malignancies, and solid tumors. Thirteen studies demonstrated OGM's ability to detect novel and clinically relevant SVs, often complementing traditional methods. Researchers also prese...
2025-12-11 13:00
